Supernus Pharmaceuticals announced the issuance of a third patent by the United States Patent and Trademark Office covering Trokendi XR, its novel once-daily extended-release topiramate product. The patent was issued by the USPTO on March 4. It provides protection for the product with expiration that is no earlier than 2027. "The issuance of this patent provides us with a broadened proprietary position with respect to our extended release formulation of topiramate. We now have patent protection on Oxtellar XR® and Trokendi XR™ through three issued U.S. patents each, and are focused on further expanding such protection,” said Jack A. Khattar, President and CEO of Supernus.